|1.||Salvemini, Daniela: 11 articles (05/2008 - 05/2002)|
|2.||Cuzzocrea, Salvatore: 9 articles (12/2005 - 07/2002)|
|3.||Mazzon, Emanuela: 5 articles (12/2005 - 07/2002)|
|4.||Masini, Emanuela: 5 articles (08/2005 - 07/2002)|
|5.||Salvemini, D: 4 articles (04/2003 - 02/2001)|
|6.||Cuzzocrea, S: 4 articles (04/2003 - 02/2001)|
|7.||Genovese, Tiziana: 3 articles (12/2005 - 06/2005)|
|8.||Muscoli, Carolina: 3 articles (08/2005 - 06/2004)|
|9.||Ndengele, Michael: 3 articles (09/2004 - 06/2004)|
|10.||Mazzon, E: 3 articles (12/2001 - 02/2001)|
05/01/2010 - "M40403 is a stable non-peptidyl mimetic of MnSOD that crosses cell membranes and is effective in reducing experimental inflammation. "
06/01/2005 - "This study shows that combination therapy with M40403 and DEX reduced the degree of chronic inflammation and tissue and bone damage associated with CIA in the rat. "
02/01/2001 - "2. As such, M40403 represents an important pharmacological tool to dissect the roles of *O2- in acute and chronic inflammation. "
06/01/2005 - "Intraperitoneal injection of M40403 (10 mg/kg daily for 8 days) significantly decreased all of the above-described markers of inflammation. "
12/01/2001 - "This study shows that a low molecular weight mimetic of SOD, M40403, attenuates the degree of chronic inflammation, tissue damage, and bone damage associated with CIA in the rat, and supports the possible use of SOD mimetics as therapeutic agents for the management of chronic diseases such as rheumatoid arthritis."
12/01/2005 - "Furthermore, combination therapy with M40403 2 mg/kg plus MTX 0.015 mg/kg exerted significant protection against the development of arthritis, similar to that observed with MTX alone at a dose of 0.15 mg/kg. In contrast, no significant protection was observed in animals treated with M40403 2 mg/kg alone or with MTX 0.015 mg/kg alone. "
12/01/2001 - "Treatment with M40403 (2-10 mg/kg/day) starting at the onset of arthritis (day 25) ameliorated the clinical signs on days 26-35 and improved the histologic findings in the joint and paw. "
12/01/2005 - "CIA was elicited in Lewis rats that had been assigned to different experimental groups, and the rats were treated daily, starting at the onset of arthritis (day 26), with M40403 2 mg/kg intraperitoneally, MTX 0.15 mg/kg orally, or combination therapy (M40403 2 mg/kg plus MTX 0.015 mg/kg). "
07/01/2002 - "2. In this study, we have investigated the cardioprotective effects of M40403 in myocardial ischaemia-reperfusion injury. "
10/08/1999 - "Injection of M40403 into rat models of inflammation and ischemia-reperfusion injury protected the animals against tissue damage. "
07/01/2002 - "Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo."
07/01/2002 - "6. Taken together, these results clearly indicate that M40403 treatment exerts a protective effect against ischaemia-reperfusion-induced myocardial injury, supporting a key role for superoxide anion in reperfusion injuries. "
07/01/2008 - "This study investigated the efficacy M40403 in a clinically relevant hamster model of acute, radiation-induced oral mucositis. "
07/01/2008 - "administered M40403 to decrease the duration and severity of oral mucositis was assessed after treatment at different doses and dosing schedules. "
07/01/2008 - "Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters."
07/01/2008 - "Similar efficacy was achieved at doses of 10 and 3 mg/kg twice daily on days -1 to 3. These results implicate free oxygen radicals in the onset of oral mucositis and also provide the basis for further development of M40403 in the prevention of this condition in at-risk cancer patients."
|4.||NF-kappa B (NF-kB)
|6.||Potassium Channels (Potassium Channel)
|9.||Hydrogen Peroxide (Hydroperoxide)